Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVE-3: Phase 3 Study of YCANTH (VP-102/TO-208) in Common Warts
jRCT2031250703Phase 3Recruiting
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in common wart comparing YCANTH (VP-102/TO-208) with Vehicle (placebo) control (2 arms). Started Jun 2026; status: recruiting.
02
Drugs
cantharidin
03
Conditions
common wart
Beyond the preview
Go deeper on jRCT2031250703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250703.